<p>Rocket Pharmaceuticals（納斯達克：RCKT - 獲取免費報告）於週四發佈了季度財報。這家生物技術公司報告本季度每股收益為（$0.42），低於分析師一致預期的（$0.41），差距為（$0.01），據 Zacks 報道。在去年同期，該公司每股收益為（$0.56）。</p>
<p>獲取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
<h2>Rocket Pharmaceuticals 股價下跌 1.1%</h2>
<ul>
<li>3 只准備大幅上漲的小型股</li>
</ul>
<p>週五午盤交易中，RCKT 股票下跌 $0.04，報 $3.63。該股票成交量為 3,682,797 股，較其平均成交量 2,125,075 股有所增加。Rocket Pharmaceuticals 的 52 周低點為 $2.19，52 周高點為 $7.39。該股票的 50 日移動平均線為 $4.09，200 日移動平均線為 $3.69。公司的市值為 $3.9611 億，市盈率為 -1.94，貝塔值為 0.52。公司的流動比率為 6.38，速動比率為 6.38，債務與股本比率為 0.07。</p>
<h2>華爾街分析師觀點</h2>
<p>多位分析師最近對 RCKT 股票發表了評論。Cantor Fitzgerald 將 Rocket Pharmaceuticals 的目標價從 $8.00 上調至 $10.00，並在 2 月 27 日的報告中給予該股票 “超配” 評級。高盛集團在 3 月 2 日的報告中將 Rocket Pharmaceuticals 的目標價上調至 $3.00，並給予該股票 “賣出” 評級。美國銀行在 3 月 30 日的研究報告中將 Rocket Pharmaceuticals 的目標價從 $8.00 上調至 $9.00，並給予該股票 “買入” 評級。Wall Street Zen 在 3 月 8 日的報告中將 Rocket Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。最後，Lifesci Capital 在 2 月 26 日的研究報告中將 Rocket Pharmaceuticals 的評級上調至 “強烈買入”。一位投資分析師給予該股票 “強烈買入” 評級，八位分析師給予 “買入” 評級，六位分析師給予 “持有” 評級，三位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，Rocket Pharmaceuticals 目前的共識評級為 “持有”，平均目標價為 $11.54。</p>
<p><strong>閲讀我們關於 Rocket Pharmaceuticals 的最新報告</strong></p>
<h2>Rocket Pharmaceuticals 的內部活動</h2>
<p>在其他新聞中，首席法律顧問 Martin Wilson 於 2 月 13 日出售了 12,253 股公司的股票，交易發生在該日。股票以平均價格 $3.31 出售，總交易額為 $40,557.43。出售後，首席法律顧問持有 683,376 股公司股票，價值約 $2,261,974.56。此次交易使其持股減少了 1.76%。該交易已在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。此外，首席執行官 Gaurav Shah 於 2 月 13 日出售了 12,279 股公司的股票，交易發生在該日。股票以平均價格 $3.31 出售，總交易額為 $40,643.49。出售完成後，首席執行官持有 1,052,045 股公司的股票，價值約 $3,482,268.95。此次交易使其持股減少了 1.15%。該銷售的 SEC 文件提供了更多信息。在過去三個月中，內部人士出售了 29,415 股公司股票，價值 $97,398。目前，21.30% 的股票由內部人士持有。</p>
<h2>Rocket Pharmaceuticals 的機構交易</h2>
<p>對沖基金和其他機構投資者最近調整了對該公司的持股。MPM Bioimpact LLC 在第二季度將其在 Rocket Pharmaceuticals 的持股增加了 141.2%。MPM Bioimpact LLC 目前擁有 3,903,081 股該生物技術公司的股票，價值 $9,563,000，此前在該期間內又購買了 2,284,816 股。Qube Research &amp; Technologies Ltd 在第二季度將其在 Rocket Pharmaceuticals 的持股增加了 690.8%。Qube Research &amp; Technologies Ltd 目前擁有 1,548,262 股該生物技術公司的股票，價值 $3,793,000，此前在上個季度又收購了 1,352,469 股。Millennium Management LLC 在第三季度將其在 Rocket Pharmaceuticals 的持股增加了 52.0%。Millennium Management LLC 目前擁有 3,570,391 股該生物技術公司的股票，價值 $11,639,000，此前在該期間內又購買了 1,221,554 股。Opaleye Management Inc. 在第四季度收購了 Rocket Pharmaceuticals 的新頭寸，價值約 $3,352,000。最後，摩根大通在第三季度將其在 Rocket Pharmaceuticals 的持股增加了 73.6%。摩根大通目前擁有 2,097,033 股該生物技術公司的股票，價值 $6,836,000，此前在上個季度又購買了 889,231 股。機構投資者和對沖基金持有該公司 98.39% 的股票。</p>
<h2>Rocket Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Rocket Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於開發針對罕見遺傳性兒童疾病的基因療法。該公司採用專有的腺相關病毒（AAV）和慢病毒載體平台，為患有遺傳缺陷的患者提供功能性基因拷貝。其項目針對一系列疾病，包括範可尼貧血、白細胞粘附缺陷 I 型和丹農病，旨在提供一次性治療，解決疾病的根本原因，而不僅僅是管理症狀。</p>
<p>該公司的產品管線包括多個處於不同開發階段的候選產品。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票超過 Rocket Pharmaceuticals</li>
<li>巴菲特花了 60 年忽視科技，賬單即將到來</li>
<li>對黃金感到興奮但不確定其走勢？試試這三種方法</li>
<li>美元處於三年低點：三家出口商悄然印鈔</li>
<li>水務基礎設施：為什麼這個乏味的行業可能會變得令人興奮</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Rocket Pharmaceuticals 嗎？</h2>
<p>在考慮 Rocket Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Rocket Pharmaceuticals 並不在名單上。</p>
<p>雖然 Rocket Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Rocket制藥

動態生物技術與基因組 ETF - Invesco

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

IBBQ

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 3 倍做多 - Direxion

醫藥突破 ETF - ALPS

標普生物技術 ETF - SPDR

<p>Rocket Pharmaceuticals（納斯達克代碼：RCKT）報告的季度每股收益為（$0.42），低於分析師預期的（$0.41），差距為$0.01。這一表現較去年同期的（$0.56）有所改善。該股下跌 1.1%，報$3.63，市值為 3.9611 億美元。分析師的評級不一，目標價格範圍從$3.00 到$11.54。內部交易活動包括總法律顧問 Martin Wilson 和首席執行官 Gaurav Shah 的股票出售。機構投資者在最近幾個月顯著增加了持股</p>

<p>Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01), Zacks reports. During the same quarter in the prior year, the business earned ($0.56) EPS.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals（納斯達克：RCKT - 獲取免費報告）於週四發佈了季度財報。這家生物技術公司報告本季度每股收益為（$0.42），低於分析師一致預期的（$0.41），差距為（$0.01），據 Zacks 報道。在去年同期，該公司每股收益為（$0.56）。</p>
</div><p>Get <strong>Rocket Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Rocket Pharmaceuticals Trading Down 1.1%</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 股價下跌 1.1%</h2>
</div><ul>
<li>3 Small-Cap Stocks That Are Ready to Rocket Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只准備大幅上漲的小型股</li>
</ul>
</div><p>RCKT stock traded down $0.04 during mid-day trading on Friday, reaching $3.63. 3,682,797 shares of the stock traded hands, compared to its average volume of 2,125,075. Rocket Pharmaceuticals has a 52-week low of $2.19 and a 52-week high of $7.39. The stock's fifty day moving average is $4.09 and its 200-day moving average is $3.69. The company has a market cap of $396.11 million, a P/E ratio of -1.94 and a beta of 0.52. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.07.</p>
<div class="lb-trans"><p>週五午盤交易中，RCKT 股票下跌 $0.04，報 $3.63。該股票成交量為 3,682,797 股，較其平均成交量 2,125,075 股有所增加。Rocket Pharmaceuticals 的 52 周低點為 $2.19，52 周高點為 $7.39。該股票的 50 日移動平均線為 $4.09，200 日移動平均線為 $3.69。公司的市值為 $3.9611 億，市盈率為 -1.94，貝塔值為 0.52。公司的流動比率為 6.38，速動比率為 6.38，債務與股本比率為 0.07。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of analysts recently commented on RCKT shares. Cantor Fitzgerald boosted their target price on shares of Rocket Pharmaceuticals from $8.00 to $10.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, February 27th. The Goldman Sachs Group raised their target price on shares of Rocket Pharmaceuticals to $3.00 and gave the stock a &#34;sell&#34; rating in a report on Monday, March 2nd. Bank of America lifted their price target on shares of Rocket Pharmaceuticals from $8.00 to $9.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, March 30th. Wall Street Zen cut Rocket Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Sunday, March 8th. Finally, Lifesci Capital upgraded Rocket Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Rocket Pharmaceuticals presently has a consensus rating of &#34;Hold&#34; and an average target price of $11.54.</p>
<div class="lb-trans"><p>多位分析師最近對 RCKT 股票發表了評論。Cantor Fitzgerald 將 Rocket Pharmaceuticals 的目標價從 $8.00 上調至 $10.00，並在 2 月 27 日的報告中給予該股票 “超配” 評級。高盛集團在 3 月 2 日的報告中將 Rocket Pharmaceuticals 的目標價上調至 $3.00，並給予該股票 “賣出” 評級。美國銀行在 3 月 30 日的研究報告中將 Rocket Pharmaceuticals 的目標價從 $8.00 上調至 $9.00，並給予該股票 “買入” 評級。Wall Street Zen 在 3 月 8 日的報告中將 Rocket Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。最後，Lifesci Capital 在 2 月 26 日的研究報告中將 Rocket Pharmaceuticals 的評級上調至 “強烈買入”。一位投資分析師給予該股票 “強烈買入” 評級，八位分析師給予 “買入” 評級，六位分析師給予 “持有” 評級，三位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，Rocket Pharmaceuticals 目前的共識評級為 “持有”，平均目標價為 $11.54。</p>
</div><p><strong>Read Our Latest Report on Rocket Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Rocket Pharmaceuticals 的最新報告</strong></p>
</div><h2>Insider Activity at Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 的內部活動</h2>
</div><p>In other news, General Counsel Martin Wilson sold 12,253 shares of the business's stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,557.43. Following the sale, the general counsel owned 683,376 shares in the company, valued at $2,261,974.56. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CEO Gaurav Shah sold 12,279 shares of the company's stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,643.49. Following the completion of the sale, the chief executive officer owned 1,052,045 shares of the company's stock, valued at approximately $3,482,268.95. This trade represents a 1.15% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 29,415 shares of company stock worth $97,398. 21.30% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，首席法律顧問 Martin Wilson 於 2 月 13 日出售了 12,253 股公司的股票，交易發生在該日。股票以平均價格 $3.31 出售，總交易額為 $40,557.43。出售後，首席法律顧問持有 683,376 股公司股票，價值約 $2,261,974.56。此次交易使其持股減少了 1.76%。該交易已在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。此外，首席執行官 Gaurav Shah 於 2 月 13 日出售了 12,279 股公司的股票，交易發生在該日。股票以平均價格 $3.31 出售，總交易額為 $40,643.49。出售完成後，首席執行官持有 1,052,045 股公司的股票，價值約 $3,482,268.95。此次交易使其持股減少了 1.15%。該銷售的 SEC 文件提供了更多信息。在過去三個月中，內部人士出售了 29,415 股公司股票，價值 $97,398。目前，21.30% 的股票由內部人士持有。</p>
</div><h2>Institutional Trading of Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 的機構交易</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the business. MPM Bioimpact LLC raised its position in Rocket Pharmaceuticals by 141.2% during the second quarter. MPM Bioimpact LLC now owns 3,903,081 shares of the biotechnology company's stock valued at $9,563,000 after buying an additional 2,284,816 shares during the period. Qube Research &amp; Technologies Ltd grew its stake in Rocket Pharmaceuticals by 690.8% during the 2nd quarter. Qube Research &amp; Technologies Ltd now owns 1,548,262 shares of the biotechnology company's stock valued at $3,793,000 after acquiring an additional 1,352,469 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Rocket Pharmaceuticals by 52.0% in the 3rd quarter. Millennium Management LLC now owns 3,570,391 shares of the biotechnology company's stock valued at $11,639,000 after purchasing an additional 1,221,554 shares during the period. Opaleye Management Inc. acquired a new position in shares of Rocket Pharmaceuticals in the 4th quarter valued at about $3,352,000. Finally, JPMorgan Chase &amp; Co. lifted its position in shares of Rocket Pharmaceuticals by 73.6% in the third quarter. JPMorgan Chase &amp; Co. now owns 2,097,033 shares of the biotechnology company's stock worth $6,836,000 after purchasing an additional 889,231 shares in the last quarter. Institutional investors and hedge funds own 98.39% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近調整了對該公司的持股。MPM Bioimpact LLC 在第二季度將其在 Rocket Pharmaceuticals 的持股增加了 141.2%。MPM Bioimpact LLC 目前擁有 3,903,081 股該生物技術公司的股票，價值 $9,563,000，此前在該期間內又購買了 2,284,816 股。Qube Research &amp; Technologies Ltd 在第二季度將其在 Rocket Pharmaceuticals 的持股增加了 690.8%。Qube Research &amp; Technologies Ltd 目前擁有 1,548,262 股該生物技術公司的股票，價值 $3,793,000，此前在上個季度又收購了 1,352,469 股。Millennium Management LLC 在第三季度將其在 Rocket Pharmaceuticals 的持股增加了 52.0%。Millennium Management LLC 目前擁有 3,570,391 股該生物技術公司的股票，價值 $11,639,000，此前在該期間內又購買了 1,221,554 股。Opaleye Management Inc. 在第四季度收購了 Rocket Pharmaceuticals 的新頭寸，價值約 $3,352,000。最後，摩根大通在第三季度將其在 Rocket Pharmaceuticals 的持股增加了 73.6%。摩根大通目前擁有 2,097,033 股該生物技術公司的股票，價值 $6,836,000，此前在上個季度又購買了 889,231 股。機構投資者和對沖基金持有該公司 98.39% 的股票。</p>
</div><h2>Rocket Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於開發針對罕見遺傳性兒童疾病的基因療法。該公司採用專有的腺相關病毒（AAV）和慢病毒載體平台，為患有遺傳缺陷的患者提供功能性基因拷貝。其項目針對一系列疾病，包括範可尼貧血、白細胞粘附缺陷 I 型和丹農病，旨在提供一次性治療，解決疾病的根本原因，而不僅僅是管理症狀。</p>
</div><p>The company's pipeline comprises multiple product candidates in various stages of development.</p>
<div class="lb-trans"><p>該公司的產品管線包括多個處於不同開發階段的候選產品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Rocket Pharmaceuticals</li>
<li>Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due</li>
<li>Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches</li>
<li>Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money</li>
<li>Water Infrastructure: Why This Boring Sector Could Get Exciting</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Rocket Pharmaceuticals</li>
<li>巴菲特花了 60 年忽視科技，賬單即將到來</li>
<li>對黃金感到興奮但不確定其走勢？試試這三種方法</li>
<li>美元處於三年低點：三家出口商悄然印鈔</li>
<li>水務基礎設施：為什麼這個乏味的行業可能會變得令人興奮</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=RCKT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Rocket Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Rocket Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Rocket Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Rocket Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Rocket Pharmaceuticals 並不在名單上。</p>
</div><p>While Rocket Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Rocket Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Rocket Pharmaceuticals（納斯達克股票代碼：RCKT）公佈財報結果